SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-21-099583
Filing Date
2021-08-03
Accepted
2021-08-03 17:29:57
Documents
2
Group Members
ANDREW J. M. SPOKESDAVID T. KIMFARALLON CAPITAL (AM) INVESTORS, L.P.FARALLON CAPITAL F5 MASTER I, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.FARALLON CA

Document Format Files

Seq Description Document Type Size
1 SC 13G tm2123569d1_sc13g.htm SC 13G 431717
2 EXHIBIT 1 tm2123569d1_ex1.htm EX-99.1 8808
  Complete submission text file 0001104659-21-099583.txt   443236
Mailing Address C/O FARALLON PARTNERS, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO CA 94111
Business Address C/O FARALLON PARTNERS, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO CA 94111 (415) 421-2132
Farallon Capital Partners, L.P. (Filed by) CIK: 0001175707 (see all company filings)

IRS No.: 943106322 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 2929 7TH STREET, SUITE 105 BERKELEY CA 94710
Business Address 2929 7TH STREET, SUITE 105 BERKELEY CA 94710 510-982-6030
Caribou Biosciences, Inc. (Subject) CIK: 0001619856 (see all company filings)

IRS No.: 453728228 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-92726 | Film No.: 211141223
SIC: 2836 Biological Products, (No Diagnostic Substances)